Abstract
Immune ch eckpoint inhibitors (ICIs) represent a milestone in advanced nonsmall cell lung cancer (NSCLC). Nevertheless, NSCLC with known oncogenic dri......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
